The PROTAC milestone: FDA approval of vepdegestrant (ARV-471) for ESR1-mutated breast cancer.
A new drug class called PROTACs showed promise in breast cancer, with the first FDA-approved version outperforming existing options in a difficult-to-treat patient group.
Vepdegestrant became the first FDA-approved PROTAC in 2026, catalytically recruiting CRBN E3 ligase to degrade estrogen receptor alpha and achieving superior PFS over fulvestrant in ESR1-mutated HR+ breast cancer. This historic approval validates the PROTAC modality and opens induced-proximity medicines as a new drug class for difficult-to-drug oncology targets.
What the study was
- Study design
- Review and regulatory milestone commentary on Phase III VERITAC-2 trial data.
- Population
- ESR1-mutated endocrine-resistant HR+ breast cancer patients (VERITAC-2 trial).
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Drug Discovery Today
Why it surfaced
First-ever FDA-approved PROTAC; historic drug-modality milestone. Phase III PFS benefit in endocrine-resistant ESR1m breast cancer. Immediately practice-relevant.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.